Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Group 1 - AngioDynamics (ANGO) has shown strong year-to-date performance, returning 9.2% compared to the Medical sector's average return of -5.6% [4] - The Zacks Consensus Estimate for AngioDynamics' full-year earnings has increased by 22.5% over the past 90 days, indicating improved analyst sentiment [4] - AngioDynamics holds a Zacks Rank of 1 (Strong Buy), suggesting it has characteristics to outperform the market in the near term [3] Group 2 - AngioDynamics is part of the Medical - Instruments industry, which consists of 85 companies and currently ranks 90 in the Zacks Industry Rank [6] - The Medical - Instruments industry has an average year-to-date loss of 8.9%, highlighting AngioDynamics' relative outperformance [6] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR has also outperformed its sector with an 18.8% return this year and a Zacks Rank of 2 (Buy) [5][7]

Core Viewpoint - AngioDynamics (ANGO) shares have seen a 1.1% increase over the past four weeks, closing at $9.60, with analysts suggesting a potential upside of 63.2% based on a mean price target of $15.67 [1] Price Targets - The average price target consists of three estimates ranging from a low of $15 to a high of $16, with a standard deviation of $0.58, indicating a strong consensus among analysts [2] - The lowest estimate suggests a 56.3% increase, while the highest indicates a 66.7% upside [2] Analyst Sentiment - Analysts show strong agreement regarding ANGO's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - A positive trend in earnings estimate revisions has been correlated with stock price movements, suggesting that this could be a reliable indicator of future performance [11] Earnings Estimates - Over the last 30 days, three earnings estimates for ANGO have been revised upward, with no negative revisions, leading to a 22.5% increase in the Zacks Consensus Estimate [12] - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Group 1 - AngioDynamics (ANGO) is currently outperforming its peers in the Medical sector, with a year-to-date return of approximately 0.9%, while the average return for the Medical group is a loss of about 7.8% [4] - The Zacks Rank for AngioDynamics is 1 (Strong Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 26% in the past quarter [3] - AngioDynamics belongs to the Medical - Instruments industry, which has an average loss of 14% year-to-date, further highlighting its strong performance relative to its industry peers [5] Group 2 - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector, with a year-to-date increase of 14.7% [4] - The consensus estimate for ANIX's current year EPS has risen by 10.9% over the past three months, and it holds a Zacks Rank of 2 (Buy) [5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has experienced a decline of 11.4% this year, indicating that ANIX is also performing well within its industry [6]

Group 1 - The core viewpoint is that AngioDynamics (ANGO) has significant upside potential, with a mean price target of $15.33 indicating a 68.3% increase from its current price of $9.11 [1] - Analysts have set short-term price targets ranging from $15 to $16, with the lowest estimate suggesting a 64.7% increase and the highest indicating a 75.6% upside, alongside a standard deviation of $0.58, reflecting a consensus among analysts [2] - There is a strong agreement among analysts regarding improved earnings estimates for ANGO, which historically correlates with positive stock price movements [4][10] Group 2 - The Zacks Consensus Estimate for ANGO's current year earnings has increased by 10.8% over the last 30 days, with no negative revisions, indicating positive sentiment [11] - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [12]

Core Viewpoint - AngioDynamics, Inc. reported better-than-expected results for the third quarter of fiscal 2025, with adjusted earnings per share (EPS) of 3 cents, compared to a loss of 16 cents in the same quarter last year and a consensus estimate of a loss of 13 cents [1][18]. Financial Performance - Adjusted loss per share on a pro-forma basis was 8 cents, improved from 16 cents year-over-year [2]. - GAAP loss per share was 11 cents, significantly better than the loss of $4.67 reported in the prior year [2][3]. - Total revenues for the fiscal third quarter were $72 million, down 4.2% year-over-year but exceeding the Zacks Consensus Estimate by 2% [4]. - On a pro forma basis, net sales were $72 million, reflecting a 9.2% increase year-over-year [4]. Revenue Breakdown - U.S. net revenues were $61.3 million, down 1.6% year-over-year, but up 9.9% on a pro forma basis [6]. - International revenues totaled $10.7 million, down 16.9% year-over-year on a reported basis, but up 5.1% on a pro forma basis [7]. Segment Analysis - Med Tech revenues were $31.3 million, up 21.3% year-over-year, surpassing projections [8][9]. - Med Device revenues were $40.7 million, down 17.6% from the previous year, but up 0.9% on a pro forma basis [11]. Margin and Expense Analysis - Pro forma gross profit increased by 15.4% year-over-year to $38.9 million, with gross margin expanding by 290 basis points to 54% [12]. - Sales and marketing expenses rose by 7.9% to $25.5 million, while R&D expenses decreased by 14.4% to $6.9 million [13]. Cash Position - The company ended the quarter with cash and cash equivalents of $44.8 million, down from $54.1 million in the previous quarter, and had no debt [15]. Guidance - AngioDynamics revised its fiscal 2025 guidance, expecting net sales between $285 million and $288 million, indicating growth of 5.3-6.4% from the previous year [16]. - Adjusted loss per share is now projected to be between 31 cents and 34 cents, an improvement from earlier estimates [17].

Revenue and Sales Performance - Revenue decreased by 4.2% to $72.0 million for the three months ended February 28, 2025, and by 8.8% to $212.3 million for the nine months ended February 28, 2025[120]. - Med Tech segment grew by 21.3% in the third quarter, while Med Device segment declined by 17.6%[120]. - Med Tech segment net sales increased by $5.5 million and $13.8 million for the three and nine months ended February 28, 2025, respectively[125]. - The company had a sales order backlog of $0.5 million as of February 28, 2025[124]. Profitability and Loss - Gross profit increased by 630 basis points to 54.0% for the three months ended February 28, 2025[120]. - Net loss decreased by $183.3 million to $4.4 million for the three months ended February 28, 2025[120]. - Total company gross profit increased by $3.0 million for the three months ended February 28, 2025, but decreased by $0.7 million for the nine months ended February 28, 2025 compared to the same periods in 2024[129]. - Med Tech segment gross profit increased by $3.7 million and $9.0 million for the three and nine months ended February 28, 2025, respectively[131]. - Med Device segment gross profit decreased by $0.7 million and $9.7 million for the three and nine months ended February 28, 2025, respectively[131]. - The company recorded a net loss of $27.9 million for the nine months ended February 28, 2025, compared to a loss of $170.9 million for the same period in the previous year[148]. Expenses and Cost Management - Research and development expenses decreased by $1.3 million and $5.2 million for the three and nine months ended February 28, 2025, respectively[134]. - Selling and marketing expenses increased by $0.1 million for the three months ended February 28, 2025 but decreased by $1.5 million for the nine months ended February 28, 2025[137]. - General and administrative expenses decreased by $0.1 million for the three months ended February 28, 2025 but increased by $1.1 million for the nine months ended February 28, 2025[138]. - Legal expenses decreased by $23.3 million and $30.0 million, primarily due to a $19.3 million settlement with BD in the prior year[144]. Cash Flow and Financial Position - Cash used in operations decreased by $4.2 million to $28.9 million for the nine months ended February 28, 2025[125]. - Cash used in operating activities was $(28,939) thousand for the nine months ended February 28, 2025, compared to $(33,159) thousand for the nine months ended February 29, 2024[145]. - Cash provided by financing activities was $5,515 thousand for the nine months ended February 28, 2025, compared to $(59,248) thousand for the same period in the previous year[145]. - Cash and cash equivalents totaled $44.8 million as of February 28, 2025, down from $76.1 million as of May 31, 2024[143]. - The company did not have any outstanding debt as of February 28, 2025 and May 31, 2024[143]. - The company has a cash balance sufficient to meet anticipated capital needs for at least the next 12 months[147]. Strategic Initiatives - The restructuring plan is expected to generate $15.0 million in annual cost savings starting in fiscal year 2027[116]. - The company repurchased 72,141 shares for $0.5 million and 171,706 shares for $1.1 million in the first and second quarters of fiscal year 2025, respectively[117]. - The company entered into agreements to sell manufacturing facilities for a total purchase price of $6.7 million[118]. - The company achieved a sales milestone related to divested products, recording a receivable of $5.5 million expected to be paid in the fourth quarter of fiscal year 2025[144]. - The company received $100.0 million from the divestiture of the dialysis and BioSentry businesses in the first quarter of fiscal year 2024[148]. Foreign Currency and Taxation - Approximately 3.5% of the company's sales were denominated in foreign currencies for the nine months ended February 28, 2025[151]. - The effective tax rate for the three months ended February 28, 2025 was 0.0%, compared to 6.0% for the same period in 2024[141]. - Unrealized foreign currency fluctuations increased by $0.1 million and $0.3 million for the three and nine months ended February 28, 2025, respectively[144]. Working Capital - Working capital was negatively impacted by a decrease in accounts payable and accrued liabilities of $18.5 million for the period ended February 28, 2025[148].

AngioDynamics Third Quarter Fiscal Year 2025 Earnings Presentation April 2, 2025 Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunitie ...

AngioDynamics (ANGO) Q3 2025 Earnings Call April 02, 2025 07:46 PM ET Company Participants Jim Clemmer - President and CEOStephen Trowbridge - Executive VP & CFOJon Young - DirectorEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants Steve Lichtman - Managing Director, Senior Research Analyst Operator Good morning, and welcome to the AngioDynamics Fiscal Year twenty twenty five Third Quarter Earnings Call. At this time, all participants are in a listen only mode. A ...

Financial Data and Key Metrics Changes - Total worldwide revenue for Q3 2025 was $72 million, representing a year-over-year growth of over 9% [9][28] - Adjusted EBITDA was $1.3 million, compared to a loss of $3.6 million in the prior year [38] - Gross margin increased to 54%, up 290 basis points from the previous year [33] Business Line Data and Key Metrics Changes - MedTech segment revenue was $31.3 million, a 22.2% increase year-over-year [28] - Mechanical Thrombectomy revenue, including AlphaVac and AngioVac, grew 46.7% year-over-year [30] - AlphaVac revenue increased by 161.4% year-over-year, reaching $3 million [30] - AngioVac generated $6.8 million in revenue, representing a 23.1% growth [30] Market Data and Key Metrics Changes - MedTech platforms comprised 44% of total revenue, up from 39% a year ago [28] - Auryon platform contributed $13.9 million in revenue, growing 17.3% compared to last year [29] - NanoKnife revenue was $6.3 million, an increase of 5.3% [31] Company Strategy and Development Direction - The company is focused on driving profitable growth in high-margin MedTech markets [10] - Plans to leverage the momentum built in the U.S. market for Auryon and expand internationally following CE marking [48] - Continued investment in clinical data and product enhancements to support long-term adoption of technologies [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity for the full fiscal year 2026 [44] - The company is monitoring the macro environment and potential tariffs but does not expect a material impact on business [34] - Increased guidance for fiscal 2025 includes revenue expectations of $285 million to $288 million, reflecting growth of 5.3% to 6.4% [45] Other Important Information - The company has secured a revolving line of credit agreement with J.P. Morgan for $25 million [41] - R&D expenses were $6.9 million, or 9.6% of sales, down from $8.1 million, or 12.2% of sales, a year ago [36] Q&A Session Summary Question: Is the $6.8 million revenue for AngioVac a good new base for the business going forward? - Management believes that $6.8 million is a solid base for AngioVac, expecting it to continue as a growth platform [54][56] Question: Can you provide details on NanoKnife's revenue and marketing efforts? - Management noted that prostate treatments have become the leading application for NanoKnife, with increasing monthly treatment rates [62] Question: What is the update on the AMBITION study and its significance? - The AMBITION study is expected to begin enrollment soon, aiming to demonstrate Auryon's effectiveness below the knee [85][88]